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ABSTRACT 
 
The ability of bacteria to live in a diversity of host environments is governed by sensors and 
response regulators in order to respond to a wide array of stressors. Escherichia coli 
encounter many stresses, during passage through mammalian gut, including acid stress. The 
AR2, glutamate-dependent acid resistance system, is controlled by a regulatory network 
which responds to stress caused by acid in E. coli. There are three known “Two component 
systems” (TCS) involved in AR2 network which are EvgAS, PhoPQ and RcsB. Till today, 
the target genes under the control of EvgAS are not very well characterized. 
 
Here, we have generated mutants and mapped them in gene encoding EvgS, the sensor kinase 
of EvgAS TCS. Using LacZ assay and acid resistance assay we characterized their 
contribution to acid resistance in E. coli K12.  
 
Furthermore, our studies focus on expression of multi-drug resistance linked to EvgAS, two 
component signaling system. In order to understand this link, active efflux studies have been 
carried out for EvgS mutants with different genetic background. This suggests that the 
EvgAS system has significant role the expression of genes that confirms resistance to the 
drugs. These ﬁndings provides a platform for better understanding of mechanism underlying 
the occurrence of multi drug resistance. 
 
Keywords: Escherichia coli, Two-component systems, EvgAS, Acid resistance, Drug efflux 
system. 
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1.1 Introduction 
Escherichia coli is a member of the Enterobacteriaceae family, which inhabit the gut of warm 
blooded mammals. Depending upon strain, they either establish commensal association with 
host by supply of vitamin K2 or can contain virulence factors capable of causing severe 
illness (Bently et al., 1982). 
 
Micro-organisms that inhabit the pH neutral environment of the mammalian gut must first 
pass through the acidic environment of the stomach. The stomach can have a pH as low as 
1.5 during starvation (Smith, 2003). Despite the lack of any clear correlation between acid 
resistance and pathogenicity acid resistance is a clinically important phenotype. This is 
because the greater an organism’s acid resistance, the lower the infective dose of that 
organism (Foster, 2004). Once in the gut, E. coli must also cope with acid shock from volatile 
fatty acids produced by fermentation. E. coli is considered to be a neutrophile and yet can 
withstand acid shock levels equivalent to acidophiles. These attributes are unusual; therefore 
E. coli acid resistance mechanisms are an interesting subject to research.  
 
1.2 E. coli acid resistance 
In 1995, Lin et al were the first to show evidence for survival of E. coli at very low pH i.e 
2.0, which was found to be dependent on the media which was used for growth and for acid 
challenge. The cultures which were grown and further tested in minimal glucose media 
without amino acids were killed due to acid stress. Yet cultures that were grown and tested in 
media rich in amino acids were able to survive at pH 2.5 for several hours, thus can be 
described as acid resistant. This extraordinary difference in phenotype forced the scientists to 
study the three acid-resistance (AR) systems. AR1 or oxidative acid resistance, the glutamate 
dependent (AR2) and arginine dependent (AR3) respectively. AR4 which is based on the 
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lysine decarboxylase, was found to be quite unsuccessful in enabling E. coli to survive 
prolonged periods of acid stress (Iyer et al., 2003). Recent work on AR4 has indicated that it 
has a more crucial role helping the cell to persist endogenous stress caused by phosphate 
starvation. The defense provided by AR2 was significantly higher than the defense conferred 
by the other AR mechanisms at extreme pH. As a consequence of this superior protective 
capability AR2 is the most studied of the acid resistance systems (Lin et al., 1996). Recently 
in addition to the mechanisms of each of the amino acid dependent systems which have been 
characterized in detail, genes located on an Acid Fitness Island (AFI) have been associated in 
acid resistance (Hommais et al., 2004). 
 
1.3 The Glutamate dependent acid resistance system (AR2) of E. coli 
AR2 is the best characterized acid stress system and is acknowledged as the glutamate 
dependent mechanism (GAD) mechanism. AR2 includes three enzymes which consist of two 
decaboxylative enzymes GadA, GadB, and a γ-amino butyric acid (GABA) antiporter. The 
glutamate decarboxylase (GAD) activity of E. coli, had already been extensively 
characterized by the time of the discovery of AR2 (Smith et al., 1992) and in addition, the 
sequences determined, the genetic loci had been mapped, and the biochemical properties 
established (De Biase et al., 1996).  As mentioned earlier, E. coli possesses two forms of 
GAD, which is encoded by two genes, gadA and gadB, located far apart on the chromosome 
(Smith et al., 1992).  The two genes are thought to have arisen by gene duplication at an early 
stage in the evolution of E. coli (Bergholz et al., 2007).  It is currently unclear whether 
functional differences arise between the two copies of this gene.  In E. coli K-12 just five 
amino acid differences exist between GadB and GadA. It is this region that has been revealed 
to be crucial for pH dependent localization of GadB to the inner membrane (Capitani et al., 
2003).  
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1.4 Mechanism of AR2 function 
During acid challenge, glutamate is transported into the cell from the extra-cellular media 
through the GadC antiporter.  Within an E. coli cell-encountering an extreme acid stress, 
GadB undergoes a conformational change to an active form as cytoplasmic pH drops to its 
pH optima between pH 3.8 to 4.6 (Capitani et al., 2003). Chloride ions, present in gastric 
secretions, increase activation of GAD activity by serving to de-repress GadB auto-inhibition 
(Gut et al., 2006). Overlying roles of the ClC H+/Cl- antiporters encoded by eriC and mriT 
may be significantly important for this activation (Iyer et al., 2002; Richard and Foster, 2004; 
Accardi and Miller, 2004). In turn GAD is employed to the cell membrane where it 
decarboxylates glutamate to gamma amino butyric acid (GABA) (Capitani et al., 2003). This 
reaction consumes an intracellular proton.  GABA is then removed from the cell by GadC in 
return for fresh glutamate.  AR2 activity seems to contribute to pH homeostasis, since after 
fermentative growth the internal pH of E. coli was found drop to pH 3.5 in the absence of 
glutamate, whereas it was measured at pH 4.2 in its presence (Richard and Foster, 2004). The 
AR2 mechanism is also reported to reverse membrane polarity from inside negative to inside 
positive, a scheme identified to be driven by acidophiles (Richard and Foster, 2004). It is 
presently not clear how effectively AR2 can function in either regard. Glutamate has a 
functional side chain with a pKa of 4.1.  Thus, during acid challenge (at pH 2.5), this side 
chain will be more than 50% protonated, whereas when it arrives, the less acidic cytoplasm 
through the GadC antiporter a substantial portion of these protons will dissociate causing a 
reduction in cytoplasmic pH before GadA/B activity integrates these into a GABA product. 
Less than 50% of GABA molecules are predicted to carry a positive charge inside the cell 
(Figure 1.1). 
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Figure 1.1 Mechanism of AR2 function during extreme acid stress at pH2.5. pKa values of ionisable groups 
on glutamate are indicated in blue boxes.  Predicted charge of the molecules is indicted in red font in brackets.  
IM = inner membrane.  OM = outer membrane.  Modified from Foster (2004).  
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 Furthermore, during extreme acid challenge, the pH in the cytoplasm drops to 3.6 (measured 
without any induced acid resistance mechanisms), the acidification of the cytoplasm lowers 
the pH  within the optimum range of the glutamate decarboxylase (3.8 to 4.6) (Capitani et al., 
2003). However, the optimum pH for arginine and lysine decarboxylases is 5.25 and 5.5 
respectively. Therefore, this environment could render the arginine and lysine decarboxylases 
ineffective (Blethen et al 1968; Lemonnier and Lane 2003). Moreover, when the arginine and 
glutamate systems are active they raise the cytoplasmic pH from pH 3.6 to 4.7 and 4.6 
respectively (Richard and Foster 2004). It is thus recommended that E. coli is endeavouring 
to repel extracellular protons by reversing the membrane potential from a negative inside, 
relative to outside, to a positive inside relative to outside (Richard and Foster 2004). This is a 
approach employed by acidophiles and could elucidate why the pH of the cytoplasm remains 
below 5 even when glutamate or argenine are present in the media (Richard and Foster 2004).  
 
1.5 Characterization of the EvgAS two-component system as an AR regulator  
Bacteria have capability to sense environmental signals and respond accordingly, which 
requires sensors and response regulators. The gap between stimulus and gene regulation is 
usually bridged by two component system (TCSs). TCSs are composed of a histidine kinase 
and a response regulator. The key feature of two-component Systems is nothing but the 
typical organization of the sensors and of the response regulators (Mascher et al., 2006). The 
variability in functional domains and their architecture in diverse conﬁgurations made several 
kinds of phosphorelay circuits. In many cases, the activation occurs through multistep His-
Asp phosphorelay cascades (Fig 1.2). In numerous cases, some protein partners have role in  
controlling the phosphorylation state of the response regulator, the ’on-off’ switch of the 
biological response which ultimately proliferates complexity of their regulation (Marie etal., 
2001). 
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EvgAS was originally characterized as a homologue of the B. pertussis virulence regulators 
BvgAS. Recently whole genome sequencing experiments resulted in the identification of 
several constitutive mutations leading to acid resistance in EvgS. All of these mutations are 
positioned in PAS domain. Each mutation conforming activation of AR2 network (Bock and 
Gross, 2002). 
 
 
 
 
 
 
 
 
 
 
Extensive studies suggested that EvgAS is a regulator of multidrug efflux pump EmrKY. 
EvgAS was implicated in acid resistance in 2002 by Masuda and Church when they observed 
increased acid resistance of strains over expressing the response regulator EvgA as compared 
to that of wild type. It was found that EvgA over-expression up-regulate many genes which 
has key role in acid resistance, including the AR2 and AFI genes (Masuda and Church, 2002; 
Nishino et al, 2003). The up-regulated genes were analogous to those found when the 
transcriptome of a constitutively active EvgS mutant strain was compared to that of a wild 
type strain (Kato et al, 2000; Eguchi et al, 2003). Successive mutagenesis of the up-regulated 
genes showed that only YdeO, YdeP and YhiE (now GadE) reduced the endurance of the 
 
Fig 1.2 Mechanisms of stimulus perception 
Schematic representation of the three different 
mechanisms of stimulus perception 
(A) HKs that sense periplasm 
(B) HKs that sense transmembrane region. 
(C) HKs that sense cytoplasm. 
 
 
The red arrow/red star  represents stimulus 
(Adapted from Mascher et al., 2006) 
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artificially induced acid resistance phenotype, and correlates them in acid resistance (Masuda 
and Church, 2002). Concisely, GadE is a member of the LysR family of transcriptional 
regulators, YdeO belongs to AraC/XylS super-family of transcriptional regulators, and YdeP 
is a nothing but putative oxidoreductase which has homology to the alpha subunit of E. coli 
formate dehydrogenase H (Schell et al, 1993; Senda et al, 2005; Masuda and Church, 2003). 
When over-expressed, these genes can independently induce an acid resistant phenotype 
(Nishino et al, 2003). YdeP over-expression had the largest impact on acid resistance, and 
GadE had the lowest impact. However, the effect of over-expression of YdeP on acid 
resistance is less than that of EvgA over-expression. The role of YdeP in acid resistance has 
not as of yet been researched any further. In contrast, the role of transcriptional activators, 
EvgA and YdeO, has been widely characterized (Ma et al., 2004).  
 
1.6 Activity of active efflux in E. coli. 
Resistance to antibiotics is widely known concept observed in wide range of bacterial species 
even those are harmful to human being. There is a miscellaneous mechanism found to 
subsidize the inherent and acquired resistance against antibiotics. The reason being resistant 
to many drugs in case of gram negative bacteria including E. coli is their typical cell structure 
and multidrug efflux pumps activity (Mark and Nick, 2009). Any antibiotic must access its 
target site(s) so as to become effective and this needs penetration through the cell envelope. It 
is found that, gram-negative bacteria, due to their double membrane structure, pose challenge 
for antibiotic accumulation. In order to target, an antibiotic has to cross the outer membrane 
which is rich in lipopolysaccharide and also should penetrate the inner bilayer of 
phospholipid, before inflowing the cell. Major inherent resistance to most of the existing 
antimicrobial compounds of Gram-negative bacteria in comparison with Gram-positive 
bacteria is mostly due to the poorer permeability of Gram-negative bacteria having double 
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membrane structure and the activity of multidrug efflux pumps (Babayan et al., 2004). To 
understand the reason behind evolving bacteria into multidrug resistant, study of 
accumulation of antibiotics and their contribution in active efflux is required (Babayan  et al., 
2004).  Multidrug efflux pumps have broad spectrum of substrate which can be used to check 
the activity by measuring accumulation of antibiotic/fluroscent substrates including Bis-
benzimide which can certainly be considered as markers of efflux activity. Variation in pump 
activity between strains indicates amount of drug accumulation into the cell and consequently 
alters fluorescence activity (Xu et al., 2003). 
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1.7 Aim and Objectives 
The literature Review has described the mechanism of acid resistance in E. coli. Earlier studies in 
this lab had created evgS mutants shown to be acid resistant. Our study was to make more mutants by 
easier and novel method, and to characterize them to understand the mechanism of action of the 
EvgS protein, and which parts of it are important for function, as well as enabling study of the genes 
which it regulates.   
 
The objective of this work was to understand the genetic changes in previously known acid 
sensitive strains which have turned into acid resistant on lab based experiments. 
In order to achieve this, following sub objectives were completed. 
 Random mutagenesis of EvgAS 
 Characterization of mutants 
 
Another objective was to understand link between EvgAS two-component system with the 
expression of multidrug resistance.              
                       
In order to achieve this, following sub objective was completed. 
 Drug efﬂux studies using Bis-benzimide (Hoescht H33342) accumulation assay 
Characterization of the evolved strains could increase our understanding of acid resistance in    
E. coli. Acid resistance is regulated by a complex network; mutations in this network could 
give rise to an acid resistant phenotype. Studying the accumulation and tolerance of such 
mutations in regulatory networks could provide insights into the robustness of bacterial 
networks. 
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2.1 Bacterial Strains, Plasmids and Primers 
The bacterial strains used in this study are listed in Table 2.1. Mutant strains were constructed 
as described in section 2.5.The plasmids used in this study are listed in Table 2.2. The 
primers used for plasmid construction and for sequencing are listed in table 2.3 and 2.4 
respectively. 
 
Table 2.1.1 Bacterial strains used in this study. 
Strain Relevant genotype Source and/or reference 
DH5α 
E. coli DH5α (F-, φ80dlacZΔM15, Δ(lacZYA-
argF)U169, deoR, recA1, endA1, hsdR17(rk-, 
mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1) 
Lab stock 
MG1655 
E. coli K-12 MG1655 (F-, lambda-, ilvG-, rfb-
50, rph-1) 
Blattner et al., 1997 
XL-1 red 
endA1 gyrA96 thi-1hsdR17 supE44 relA1lac 
mutD5 mutS mutt Tn10(Tet
r
)
a
 
Aglient Technologies,UK 
BW25113 
 
BW25113 (lacI qrrnBT14 ΔlacZWJ16 
hsdR514 Δara BAD AH33 ΔrhaBADLD78 
Datsenko et al.,2000 
 
Table 2.1.2 Plasmids used in this study 
Plasmid Description Source and /or reference 
pBAD/Evgs-his 
cloning the evgS gene into pBAD-TOPO 
using the NcoI and PmeI sites 
Yoko Eguchi and Ryataro 
Utsumi 
pBAD/Evgs-his/  
ΔCla 
ClaI digest of the pBAD.evgS.his and 
pBAD, and re-ligation of these to close the 
gap.  
Rob Marshall, Student from 
Lab 
pBAD/Evgs-his/  
ΔSwa-Psi 
SwaI PsiI double digest of the 
pBAD.evgS.his plasmid, and a blunt-end 
ligation to close the gap 
Yandong Xia, M.sc Student 
from Lab 
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Table 2.1.3 Primers used in this study 
Primer Name Sequence (5’-3’) Purpose 
acrA Forward Primer AATGCCAGTAGATTGCACCG PCR Screening: 
MG1655/pBAD24/ ΔacrA 
acrA Reverse Primer GCAATCGTAGGATATTGCGC PCR Screening: 
MG1655/pBAD24/ ΔacrA 
Kanamycin Forward 
Primer 
CCTGCAAAGTAAACTGGATG PCR Screening: 
MG1655/pBAD24/ ΔacrA 
Kanamycin Reverse 
Primer 
CATGCTCTTCGTGCAGATCA PCR Screening: 
 MG1655/pBAD24/ ΔacrA 
evgS FP+1081 GAGGATGGGATATAATAC 
 
Gene Cloning: 
MG1655/pBAD/EvgS-his 
mutant 
evgS RP +2461 GCAAAGGACTTGTAATGG 
 
Gene Cloning: 
MG1655/pBAD/EvgS-his 
mutant 
 
 
 
pydePtet 
Derived from pLUXydePp by insertion of 
pBR322 tetR gene fragment including 
ribosome binding site,downstream of the 
promoter ydePp 
Made by Rachel Chandler, an 
undergraduate student from 
lab 
 
pevgAS 
Derived from pZC320 by insertion of evgAS 
operon of E.Coli MG1655 
Matt by Matt Johnson, PhD 
student 
pCP20 
Gene mutagenesis plasmid; ApR and CmR; 
ts replicon curable at  43°C; encodes FLP 
recombinase for FLP mediated excision of 
DNA between FRT sites 
Cherepanov  et al.,1995 
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Table 2.1.4 Primers used for sequencing 
Primer Name Sequence (5’-3’) Purpose 
evgS-110_FP CAGCAACAAAAGCATTGCC 
 
Sequencing of evgS gene. 
evgS+79_RP CGTCTGCTTCTTCTAATGTAGC 
 
Sequencing of evgS gene. 
evgS FP+1081 GAGGATGGGATATAATAC 
 
Sequencing of evgS gene. 
evgS_FP-1281 GGAGGTTGAATGGATACAGG 
 
Sequencing of evgS gene. 
evgS_RP+1330 
 
CGCGACGTAAAGTGTTCC Sequencing of evgS gene. 
evgS_FP+2278  CACTCCTCGGCTTAATTG 
 
Sequencing of evgS gene. 
evgS RP +2461 GCAAAGGACTTGTAATGG 
 
Sequencing of evgS gene. 
evgS_RP+3679 
 
GAGGACCGCTTAAACAAG Sequencing of evgS gene. 
 
 
2.2. Growth conditions 
(A) E. coli was grown at 37°C, unless stated and with aeration at 180 rpm in shaking 
incubator.  LB media ( 1% w/v tryptone, 0.5% w/v yeast extract, 1% w/v salt; pH 7) was used 
for standard growing conditions. LB agar (LB broth + 1.5% w/v bacto agar; pH 7) was used 
where plating of bacteria was required. Both LB and LB agar were made up in distilled water 
and sterilized by autoclaving. 
 
(B) For P1 Transduction, Lennox Broth 0.5% w/v tryptone, 0.25% w/v yeast extract, and 
0.25% w/v salt; pH 7) was used for growing conditions.  Lennox Broth + 1.25% Nutrient 
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Agar; pH 7 was autoclaved prior to use, when sufficiently cooled, 40% glucose (1mL per 
200mL of LB) and 0.1M CaCl2 (4 mL per 200 mL of LB) was added which was used where 
plating of bacteria was required. Soft agar overlay tubes” (LB + 0.75% bacto agar; autoclaved 
20 minutes; maintained in 3ml as single use aliquot which was placed in the waterbath at 
45
O
C prior to use).This was used to make bacterial lawns for P1 phage infection.  
 
(C) M9 media based on M9 salts; pH 7 (Table 2.3) was used in P1 Transduction protocol for 
washing steps.  
Appropriate selection of resistance tagged strains and plasmids, antibiotics were added to 
growth media as follows., ampicillin (Ap), 100μg/ml; kanamycin (Km), 50μg/ml; tetracycline 
(Tet) 6μg/ml.   
 
Table 2.3 Composition of M9 media.  
Compound Chemical formula working concentration 
di-Sodium hydrogen orthophosphate  Na2HPO4 42.3mM 
Potassium dihydrogen orthophosphate KH2PO4 22.1mM 
Sodium chloride NaCl 8.56mM 
Ammonium chloride NH4Cl  18.7mM 
D-Glucose (anhydrous) C6H12O6 0.4% w/v; 22.2mM 
Magnesium sulphate MgSO4 2mM 
Calcium chloride1  CaCl2 0.1mM 
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2.4 General Molecular Biology Techniques  
2.4.1 Plasmid Preparation                                                                                         
This method is used to isolate the plasmid DNA from bacterial cell overnight culture 
containing appropriate antibiotic. The cells were obtained by centrifugation at 12,000 rpm for 
5 min. The cell pellet was suspended in 200 µl of solution I (Glucose 50 mM, EDTA 10 mM, 
Tris 25 mM, pH 8) and incubated at RT for 5 min. Subsequently, the cells were lysed by 
adding 400 µl of freshly prepared solution II (1%SDS, 0.2 m NaOH) and gently mixed by 
inversion. To this 300 µl of solution III (3M Sodium Acetate, pH 5.2) was added, mixed 
thoroughly by inversion and incubated at RT for 5 min. The mixture was then centrifuged at 
13,000 rpm for 5 min. The supernatant was collected and centrifuged again at 13,000 rpm for 
5 min at to get clear supernatant. The DNA was precipitated with 600 µl of isopropanol and 
centrifuged at 13,000 rpm for 15 min and washed with 70% ethanol at 13,000 rpm for 10 
min. The pellet was then air dried and dissolved in TE/autoclaved distilled water that is free 
of DNase contamination.  
 
2.4.2 Preparation of competent cells 
One ml appropriate overnight culture was diluted to 100ml fresh LB media in a 500ml 
conical flask.  This was grown at 37°C (or as appropriate if temperature selective plasmid) 
with shaking (180rpm) until the culture reached an OD (A600nm) of 0.3-.0.35. It was 
followed by incubation on ice for 30 min. The cultures were then pelleted (8,000 rpm, 4°C, 
10 minutes) the supernatant removed by decanting then the pellet was re-suspended in 0.1v/v 
ice cold TSS (0.5 ml DMSO, 1gm PEG-3350,0.2 ML 1M MgSO4, pH 6.5.All dissolved in 10 
ml LB).It was split into 100µl aliquots for the use of transformation. 
 
 
17 
 
2.4.3 Plasmid Transformation  
(A) An aliquot of competent cells was thawed on ice and plasmid DNA (~50-70 ng) was 
added to it and the contents were mixed properly by swirling the eppendorf gently. The 
mixture was kept on ice for 30 minutes. 0.9 ml TSR (LB supplemented with 20 mM Glucose 
was added to it and incubated at 37°C for 1 hour  in a shaker incubator. The transformed cells 
were then spin at 6000 rpm for 5 minutes. Supernatant was decanted, with the exception of 
100uL and resuspended the pellet in this 100uL and plate onto selective agar. 
 
(B) If XL-1 Red competent cells were used for transformation, 25mM β-Mercaptoethanol 
was added into the 100µl of competent cells prior to use. An aliquot of competent cells was 
thawed on ice and Plasmid DNA (~50-70 ng) was added to it and the contents were mixed 
properly by swirling the eppendorf gently. The mixture was kept on ice for 30 minutes. This 
was followed by heat shock treatment at 42°C for 45sec.Then it was incubated on ice for 2 
minutes. 0.9 ml LB was added to it and incubated at 37°C for 1 hour in a shaker incubator. 
The transformed cells were then spinning at 6000 rpm for 5 minutes. Supernatant was 
decanted, with the exception of 100uL and resuspended the pellet in this 100uL and plate 
onto selective agar (Ampicillin in this case). 
 
2.4.4 Preparation of electrocompetent cells 
Four ml overnight culture was scaled up to 400ml fresh LB media in a 1L conical flask.  This 
was grown at 37°C (or as appropriate if temperature selective plasmid) with shaking 
(200rpm) until the culture reached an OD (A600nm) of 0.6. The Heat Shock at 42°C was 
given to the culture in shaking condition, 180 rpm for 30 minutes. Further culture was shifted 
on ice and heat shock at 4°C was given by keeping the culture at 180 rpm. The cultures were 
then pelleted (4000 rpm, 4°C, 30 minutes).The supernatant removed by decanting and then 
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the pellets re-suspended in 100 ml 20% glycerol (filter sterilized) and 1 mM MOPS (20.9% 
W/V,pH 7.5).  The cells were then re-spun and re-suspended further two times.  After the 
third re-suspension the cells were spun down, the supernatant carefully removed and finally 
the cells re-suspended in 2mL of ice cold 20% glycerol and 1mM MOPS. In all cases aliquots 
were used for electroporation on the same day. 
 
2.4.5 Electroporation 
3-4 μl of DNA was added to 80 μl of electrocompetent cell aliquots and mixed by flicking.  
Electroporation cuvettes (Geneflow, Fradley, UK; 1mm gap) were pre-chilled prior to use.  
The competent cell/DNA mix was pipetted into the electroporation cuvette.  The samples 
were then electroporated at 1800V (1mm) 2200 V (2mm) (Geneflow electroporator). 1 ml LB 
was added to it and it was shifted to 15 ml Falcon tubes and incubated at 37°C for 1 hour in a 
shaker incubator. The transformed cells were then spin at 6000 rpm for 5 minutes. 
Supernatant was decanted, with the exception of 100uL and resuspended the pellet in this 
100uL and plate onto selective agar. 
*In the case of pCP20 transformants, select for ampicillin was used for selection and culture 
was incubated overnight at 30
o
C. 
 
2.5 Random Mutagenesis of EvgS 
pBAD EvgS-His was transformed into E. coli XL-1 Red competent cells, as described in 
section 2.4.3 (B). This strain is particularly suitable for generating random mutations within a 
gene as previous studies state that XL-1 Red is deficient in three of the primary DNA repair 
pathways and it has no selectable/ screenable phenotype. The transformed plate was divided 
into 8 sections in order to prepare the transformants plasmid using alkaline lysis method as 
described in section 2.4.1.The obtained 8 plasmids were further transformed into DH5α -
19 
 
pydePtet competent cells as described in section 2.4.3 (A). Selection of each plasmid was 
done by 2 different types of antibiotic combination as described below. 
1. LB Agar containing Ap, Km and Tet: To check for mutants. 
2. LB Agar containing Amp and Kan: To check efficiency of transformants. 
Ampicillin (Ap), 100μg/ml; kanamycin (Km), 50μg/ml; Tetracycline (Tet) 6μg/ml.   
 
The colonies obtained on Amp/Kan/Tet plate was taken forward in order to prepare the 
plasmids, which were further transformed into pydep-lacZ cells and plated on amp/kan plate 
in order to get putative mutants. Further, below studies were carried out for putative mutants. 
 Sequencing and data analysis 
 Check for lacZ activity 
 Acid Resistance Assay 
 Acid Resistance V/S LacZ activity  
 
2.6 Sequencing and data analysis 
Plasmid DNA was sequenced using specific primers in the University of Birmingham 
Functional Genomics Laboratory, Plasmid to Profile sequencing (Birmingham, UK). 
Analysis was done to confirm the single amino acid change in the given sequence. This was 
carried out with the help of basic bioinformatics tools including Expasy Translate, Protein 
BLAST etc. (Section 3.1). 
 
2.7 LacZ activity 
EvgS putative mutants obtained were used for this assay along with active evgS mutants that 
had previously isolated in the lab as a positive control and pBAD24 (vector only) as a 
negative control. These were inoculated into 5ml LB broth containing ampicillin and 
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kanamycin at 37°C for 3-4 hours in a shaker incubator till the OD600 reaches to 0.35-0.4. For 
each culture OD600 was measured separately. At this point,0.1 ml of culture was mixed with 
0.9 ml of Z buffer (0.5M Na2HPO4,0.5M NaH2PO4,1M KCl, 1M MgSO4 0.27% β -
Mercaptoethanol). Cells were lysed using 0.1 % SDS and 40 µl CHCl3 followed by vortexing 
for 8-10 sec. Reaction was started by adding 0.2 ml ONPG followed by incubation at 30°C 
till getting the yellow color of reaction mixture. Incubation time was measured for the 
calculation of LacZ activity. Reaction was stopped by adding 0.5ml 1M Na2CO3. 1 ml 
reaction mixture was taken and spin at 10,000 rpm for 10 minutes. Supernatant was taken in 
fresh cuvette in order to measure the absorbance at 420 nm. LacZ activity was measured 
using the formula described below. The Graph was plotted accordingly (Fig 3.2). LacZ 
activity= OD420/ (OD600*Volume of reaction mixture in ml*Incubation time) 
 
2.8 Acid Resistance Assay 
Strains of EvgS mutants.to be assayed were inoculated in 5 ml LB, (containing appropriate 
antibiotic) overnight at 37°C, 180 rpm. 500 µl cultures from each tube was diluted into fresh 
5 ml LB. Diluted cells were grown for 2 hours 37°C,180 rpm. At the end, the cells were in 
exponential phase, where acid resistance was measured.  
 
A 96 well plate was used to dilute the cultures into pH 2.5and pH 7.0 LB medium. The plate 
was setup by adding 180 µl of LB, pH 2.5 into 6 wells in a row. The same was repeated for 
LB, pH 7.0.Then the plate was prewarmed at 37°C for 20 minutes prior to start the assay. 10 
fold serial dilutions were carried out using the cells at exponential phase for both the rows. 
The 10
-2
 to 10
-6
 dilutions were immediately spotted onto square LB plates (containing 
appropriate antibiotic) using multi tip pipette. Once spotted, the plates were tilted to spread 
the spots into the line down the plate (Fig 2.1). Plates were incubated at 37°C overnight. 
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The survival of each strain was expressed as percentage, which was calculated by dividing 
the number of colonies from pH 2.5 dilutions by the number of colonies from pH 7.0 
dilutions and multiplied by 100.The most concentrated dilution that could be counted was 
used. The graph for % survival at pH 2.5 with respect to pH 7.0 for each mutant was plotted 
(Fig 3.3). 
 
                                                              
 
Figure 2.1  Example of an acid resistance assay.  
The figure shows the  colonies from an acid resistance assay. The dilution factors are shown in  to top of the 
figure and the pH values are at the bottom. Colonies were counted by eye. 
 
2.9 Acid Resistance V/S LacZ activity  
The graph was plotted in order to analyze the correlation between % Acid Resistance and 
LacZ activity of the EvgS mutants (Fig 3.4). 
 
2.10 Cloning: A) PBAD EvgS his mutant B) PBAD EvgS his mutant ∆Swa-Psi 
2.10.1 PCR amplification  
EvgS mutants were used as a template for amplification. Primers, FP +1081 and RP +246 
were used for PCR amplification. (Refer Table 2.3). Gradient PCR machine was used to 
DILTUTIONS 
 
 10-2    10-3    10-4     10-5     10-6       10-2      10-3     10-4      10-5   10-6  
 
 
 
10
-3 
 
10
-3 
10
-3 
 
10
-3 
 pH 2.5 pH 7.0 
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amplify the gene and standardize the annealing temperature. Gradient was kept between 40°-
50°C. The amplified products were checked on 1% agarose gel and the size confirmed by 
loading a 1kb DNA ladder. For further PCR reaction 45ºC was kept as annealing temperature 
as it was found to be appropriate temperature from gradient PCR.  
 
2.10.2 Restriction digestion of vector and inserts  
Once the amplified genes were obtained, restriction digestion was carried out for the vectors 
pBAD/EvgS-his/ΔCla and pBAD/Evg-his/Δcla-ΔSwa-Psi (which was obtained from lab, 
Previous unpublished work) With ClaI. Three independent EvgS mutants,A,B and C were 
also cut with the same restriction enzymes to generate sticky ends so that both the vector and 
the insert can be ligated under appropriate conditions. 
 
2.10.3 Ligation 
The digested vector with gene insert (In molar ratio 1:3) were then ligated with the help of T4 
DNA ligase in a reaction mix containing ligation buffer in final concentration of 1X. The 
ligation was carried out at 16°C for 16 hours as the optimal activity of the enzyme was at 
16°C.  
2.10.4 Transformation and further studies 
The ligated product then transformed into pydep-lacZ cells and plated on amp plate for 
overnight incubation. Following studies were carried out. 
 Plasmid Preparation followed by restriction digestion with SalI for all 6 transformants 
(Fig 3.5-A) 
 LacZ activity for all 8 transformants as described in Section 2.7 (Fig 3.5-B). 
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2.11 Phage P1 transduction  
BW25113/ ΔacrA which was a donor bacteria was grown in 1 mL of Lennox Broth and 2% 
0.1M CaCl2  overnight at 180rpm, 37
o
C.The culture was diluted with fresh LB and it was 
returned on shaking incubator at 37
O
C and 180 rpm for approximately 5 hours.  
The P1 stock was diluted to 10
-5
 using 10
-3
, 10
-4
, 10
-5
 stocks using Lennox Broth in sterile 
glassware. It was Stored in the fridge till required 
When the donor bacteria was thick 0.1mL of  P1 10
-3/4/5
 (only 1 stock) was added to the soft 
agar overlay tubes in the waterbath (Section 2.2-B), 0.1mL of donor bug was added, vortex 
and poured directly onto Lennox Agar plates (Section 2.2-B).This was repeated for all 3 
dilutions (10
-3/4/5
) of P1 stock. Plates were incubated at 37
O
C, with the lids uppermost (i.e not 
inverted), incubated towards the end of the day to prevent overgrowing of bacteria. Overnight 
culture of recipient bacteria (that to be infected with P1, here E. coli MG1655) in 1mL of LB 
was prepared and incubated at 37
O
C, 180rpm.On the following day, all the plates were 
examined and plate that shows a ‘lacey plaque’ effect were selected. To harvest the plate, 
glass homogeniser was prepared and stored on ice, to keep chilled. 1mL of chloroform was 
added to the homogeniser and returned to ice. To harvest the selected plate, 2mL of Lennox 
Broth was added to the surface and carefully removed the upper layer using a glass spreader 
and transferred to a glass homogeniser. It was homogenised until the mixture was smooth, 
whilst being stored on ice. The homogenised mixture was transferred to thick walled protein 
tubes (thick walled test tubes) and centrifuged at 2870rpm for 15 minutes. Supernatant was 
transferred to sterile glassware, containing 1mL chloroform, vortex and stored at 4
O
C – This 
was the P1 stock required for transducing the recipient bacteria. P1 stock was diluted to 10
-1
 
and 10
-2 using
 LB. The recipient bacteria overnight culture (1mL) was transferred into 20mL of 
LB and returned to the incubator until thick (approximately 5 hours).Further it was 
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centrifuged at 2870rpm for 3 minutes. Pellet was resuspended in 0.5mL of LB. To the tubes 
following was added; 
1.  0.1mL concentrated P1 stock 
2.  0.1mL 10-1 P1 Stock 
3.  0.1mL 10-2 P1 Stock 
4.  Nothing – Negative Control 
The tubes (not shaking) were incubated in a waterbath for 20 minutes 1mL of 1x M9 media 
(Section 2.2-C) was added and centrifuged at 2870rpm for 3 minutes. Pellet was resuspended 
in 4mL of M9 media, centrifuged at 2870rpm for 3 minutes, supernant was disguarded. 
Above step was repeated until the cells have been washed 3-4 times, to remove any excess P1 
stock. Pellet was resuspended in 2mL of LB and placed in the shaking incubator at 37oC, 180 
rpm for 1 hour, to allow the cells to recover. Centrifuged as above and pellet was resuspended 
in 0.2mL of 1x M9 media, and plated onto selective agar plates for overnight incubation. On 
the following day, the plates containing recipient bacteria and various P1 stocks were 
examined and colonies were selected for screening using colony PCR. The reactions were 
then run in a thermal cycler set to the following programme. 
 
 
 
 
 
The 1% agarose gel was run in order to confirm the transfer of mutation into MG1655   
Steps Temp Time 
30 cycles 
Initial denaturation 95°C 2 min 
Denaturation 95°C 30 sec 
Annealing 56°C 30 sec 
Extension 72°C 1.5 min 
Final Extension 72°C 5 min 
25 
 
2.12 Removal of kanamycin resistance cassette                                                               
Once transfer of mutation into MG1655 was confirmed, In order to remove kanamycin 
cassette within, the electrocompetent cells were prepared from P1 MG1655 strain (Section 
2.4.4) The gene mutagenesis plasmid, pCP20 was prepared (Section 2.4.1).As this is 
temperature sensitive plasmid, overnight incubation (prior to start the miniprep) was done at 
30°C. The Pcp20 plasmid was then transformed into competent cells made from strain of 
MG1655 containing the arcA:: kan marker (which had been introduced by P1 transduction) 
using electroporation method. (Section 2.4.5)  and the transformants were plated onto LBA 
containing ampicillin 100ug/mL and incubated overnight at 30oC.On the next day,  10 
colonies were picked and inoculated into 5mL LBB (containing no antibiotics) and was 
Incubated at 42
o
C, 180 rpm for at least 6 hours. The culture was streaked in order to get the 
single colonies onto LBA Only plates – Again containing no antibiotics and incubated 
overnight at 37
o
C.On the following day. Total 25 colonies were Picked across all the plates 
and patched the samples onto LBA only (all should grow), LBA containing ampicillin (to 
check the loss of pCP20) and LBA containing Kanamycin. The plates were incubated at 37
o
C 
overnight. The plates were examined, only colonies which have grown on the LBA only and 
not on the plates containing either antibiotic have been selected. Colony PCR was performed 
(Section 2.11) to confirm the absence of the antibiotic resistance cassette (Fig 3.6-B). This 
was then taken forward for efflux assays. 
 
2.13 Efflux assay using Hoescht 33342  
2.13.1 Strains preparation 
MG1655/pBAD24/ΔacrA, after getting rid of Kanamycin cassette was then processed to 
prepare the competent cells (section 2.4.2).Following list of plasmids with MG1655/pBAD24 
background were transformed (section 2.4.3-A) into above mentioned competent cells in 
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order to get the new strains with ∆acrA background. Thus total 16 strains (each strain with 
MG1655/pBAD24 and MG1655/pBAD24/∆acrA background) then processed for efflux 
assay. 
Strains used were for this experiment were as follows: 
1. pBAD 24 (Vector only)             5. Constitative EvgS Mutant A 
2. pBAD-EvgS –his                       6. Constitative EvgS Mutant B 
3. pBAD-EvgS/ΔCla                     7. Constitative EvgS Mutant C 
4. pBAD-EvgS/ΔSwa-Psi    8. Constitative EvgS Mutant D 
 
2.13.2 Bis-benzimide (Hoescht H33342) accumulation assay 
The strains mentioned above were inoculated in 5ml LB containing appropriate antibiotic and 
incubated overnight at 37
o
C.Cells were harvested at 10,000 rpm for 10 minutes at RT. Pellet 
was resuspended in 3 ml of PBS (0.1 M pH 7.2). Appropriate dilutions were made using PBS 
for each sample so as to reach OD600 of to 0.1. 
 
2.13.3 Hoescht stock preparation: 
Bis-benzimide (Hoescht 33342) was dissolved in sterile water to give 25 ml of 1 mM H33342 
(13.35 mg/ml) in a volumetric flask. This stock was then diluted further to 25 µM in 10 ml of 
sterile water in a volumetric flask for further use. 
 
2.13.4 Efflux Assay 
The diluted suspensions of each strain were added (180 µl each) in triplicates to a black 
plastic 96 well plate. 200 μl of PBS was added into the 4 wells which were acted as a blank.  
Before placing microtitre tray in Fluostar machine, following things were checked including 
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configuration of plate reader, position of optic leads, value of excitation and emission 
wavelengths, volumes of bis benzimide for addition and setting of “gain” at 1460.Once this is 
done, the 96 well plate was placed in the machine tray .The stock of 25 µM H33342 was 
placed into the FLuoSTAR machine and program was set so that, 20 µl of H33342 would be 
injected to all the wells containing 180 μl of sample at cycle number 3.The fluorescence was 
measured with excitation and emission (355nm and 465nm) every min for 1 hour at 37
o
C.The 
Graphs were plotted and data was analyzed (Fig 3.7 A-G). 
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CHAPTER 3 
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3.1 Random Mutagenesis of EvgS 
Previous work in the Lund laboratory showed that selection for high levels of acid resistance 
in exponential phase resulted in strains that contained mutants in the PAS domain of the 
sensor kinase, EvgS. These showed constitutive activation of the genes of the acid resistance 
pathway (Johnson, 2011). These mutants have the potential to increase our understanding of 
the mechanism of action of the EvgS protein, and which parts of it are important for function, 
as well as enabling study of the genes which it regulates.  However, the method of using 
selection for acid resistance is relatively slow.  In order to obtain more mutants in the evgS 
gene, a novel selection has been set up in the lab where the evgA-regulated promoter of the 
ydeP gene was fused to a tetracycline gene, and it was confirmed that strains carrying this 
fusion were only tetracycline resistant when they also contained a constitutively active evgS 
mutant. Thus, new constitutive mutants in EvgS can be found by mutating a plasmid carrying 
the evgS gene, transforming it into strains carrying the pydeP-tet fusion, and screening for 
tetracylcine resistance.  The plasmid pBADevgAS was mutagensised by passage through the 
XL-red mutator strain, extracting from the strain, and transformed into the strain carrying the 
pydeP-tet plasmid. Cells were plated onto tetracycline at 6 ug/ml. 9 colonies were found that 
were resistant to tetracycline. Plasmid DNA of putative mutant strains were sequenced using 
specific primers in the University of Birmingham Functional Genomics Laboratory.  
 
The region from EvgS (Escherichia coli str. K-12 MG1655) is shown (Chart 3.1). 
 
The mutations are shown with the mutated amino-acid above the wild type one.  The DNA 
sequence shown is the WT sequence.  
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Mutants found by me are in highlighted in blue color. Additionally, previously established 
mutants by Matthew Johnson (Ph.D student from Dr. Lund’s laboratory) are also shown in 
yellow.  Mutants found by Ryutaro Utsumi's group in Japan are in green. The PAS domain is 
shown in bold. 
  G  S  S  L  L  W  G  F  Y  L  L  R  S  V  R  R  R  K  V  I 
TGGCAGTAGCCTTTTATGGGGATTCTACCTGTTACGCTCAGTTCGTCGTCGTAAAGTCAT 1700 
accgtcatcggaaaatacccctaagatggacaatgcgagtcaagcagcagcatttcagta   
                
                 L  P        S              P     F 
  Q  G  D  L  E  N  Q  I  S  F  R  K  A  L  S  D  S  L  P  N 
TCAGGGTGATTTAGAAAACCAAATATCATTCCGAAAAGCACTCTCGGATTCCTTACCGAA 1760 
Agtcccactaaatcttttggtttatagtaaggcttttcgtgagagcctaaggaatggctt 
 
                                      I 
  P  T  Y  V  V  N  W  Q  G  N  V  I  S  H  N  S  A  F  E  H 
TCCAACTTATGTTGTAAACTGGCAAGGTAATGTCATTAGTCATAATAGTGCTTTTGAACA 1820 
Aggttgaatacaacatttgaccgttccattacagtaatcagtattatcacgaaaacttgt 
 
 
  Y  F  T  A  D  Y  Y  K  N  A  M  L  P  L  E  N  S  D  S  P 
TTATTTCACTGCGGATTACTACAAAAATGCAATGTTACCATTAGAAAACAGTGACTCACC 1880 
Aataaagtgacgcctaatgatgtttttacgttacaatggtaatcttttgtcactgagtgg 
 
                                               E  
  F  K  D  V  F  S  N  A  H  E  V  T  A  E  T  K  E  N  R  T 
CTTTAAAGATGTTTTTTCTAATGCGCATGAAGTCACAGCAGAAACGAAAGAAAATCGAAC 1940 
Gaaatttctacaaaaaagattacgcgtacttcagtgtcgtctttgctttcttttagcttg 
 
                                A 
  I  Y  T  Q  V  F  E  I  D  N  G  I  E  K  R  C  I  N  H  W 
AATATACACACAGGTATTTGAAATTGATAATGGCATCGAGAAAAGATGCATTAATCACTG 2000 
Ttatatgtgtgtccataaactttaactattaccgtagctcttttctacgtaattagtgac 
 
         R   
H  T  L  C  N  L  P  A  S  D  N  A  V  Y  I  C  G  W  Q  D 
GCATACATTATGCAATCTTCCTGCAAGTGACAATGCAGTATATATTTGTGGTTGGCAAGA 2060 
Cgtatgtaatacgttagaaggacgttcactgttacgtcatatataaacaccaaccgttct 
 
                                         G 
  I  T  E  T  R  D  L  I  N  A  L  E  V  E  K  N  K  A  I  K 
TATTACTGAAACGCGTGATCTAATTAATGCACTCGAGGTAGAAAAAAATAAAGCGATAAA 2120 
ataatgactttgcgcactagattaattacgtgagctccatctttttttatttcgctattt 
 
  A  T  V  A  K  S  Q  F  L  A  T  M  S  H  E  I  R  T  P  I 
GGCTACCGTAGCAAAAAGTCAGTTTCTGGCAACGATGAGTCACGAAATAAGAACACCAAT 2180 
ccgatggcatcgtttttcagtcaaagaccgttgctactcagtgctttattcttgtggtta 
  
 
 
 
Chart 3.1 
The region containing mutations from EvgS (Escherichia coli str. K-12 MG1655)  
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The list of primers used for sequencing the whole evgS gene is provided in table 2.4 from the 
section, materials and methods. The important observation to be noted here as, after 
sequencing the whole evgS gene in each case and found no other mutants. 
The description of mutations, their position and is described. (Table 3.2) 
 
As far as reason for repetition of the mutation/s is considered, there can be 2 possibilities, 
First, it may be that several independent mutations have indeed occurred at the same 
position.  Although the chances against this are high, they may still be found if there are only 
a very few mutations allowing a particular phenotype to occur. Second, it may be that the 
colonies containing the mutation are descended from the same original mutant.  Our 
experimental design does make the second possibility quite possible, therefore if to get more 
independent mutants, several repeats of the original mutagenesis experiment which are 
completely independent of each other can be carried out. 
 
It is also observed that, these mutations in EvgS are located in the PAS domain. Previous 
studies showed that E. coli has 3 main acid resistance mechanism and each mechanism 
requires different amino acid to function. (Lin et al., 1996).Thus finding and understanding 
the contribution of these mutants to the acid resistance phenotype is required to characterise 
them. In order to check this hypothesis, same strains were taken forward for LacZ activity 
and acid resistance assay. 
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  Serial number 
(same mutation also 
found in) 
Mutation Position No. Of times, this 
mutation found 
A - Q→P 
 (Glutamine to Proline) 
574 1 
B E,F,G,H,I S→P 
(Serine to Proline) 
582 6 
C - K→E 
(Lysine to Glutamic acid) 
643 1 
D J C→R 
( Cysteine to Arginine) 
671 2 
 
Table 3.1 The description of mutations 
The table explains mutated amino acid and it’s position in EvgS  (Escherichia coli str. K-12 MG1655). 
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3.2 LacZ activity of EvgS mutants 
It is known that, in order to understand gene regulation in bacteria, the promoter of interest is 
either linked on plasmid/phage vector or to a reporter gene such as lacZ. The promoter 
activity of such lacZ-based vectors is assessed by measurements of β-galactosidase. This 
particular enzyme is very stable and thus easy to assay (Sung et.al., 1998). In our study, the 
plasmid pBADevgAS was mutagensised by passage through the XL-red mutator strain, 
extracting from the strain, and transformed into the strain carrying the pydeP-tet plasmid. 
pydeP is fused with reporter gene lacZ. pydep is strongly upregulated by evgA, therefore, this 
this promoter is a good choice for this assay.  
 
In order to check the effect of EvgS mutations on the activity of AR2 network, strains were 
assayed for lacZ activity as described in materials and methods. The already studied and 
showing lacZ activity mutant was taken as positive control, whilst pBAD 24 (Vector only) 
was taken as negative control. The Fig 3.2 explains the pattern of LacZ activity for EvgS 
mutants. Each assay was done in triplicates and standard deviation was calculated (Fig 3.2). 
 
The level of lacZ activity for different mutant differs; this is may be due to the structural 
location of each mutant in the PAS domain. Consequently each mutation can alter possible 
signaling in two component system at different level which can leads to difference in lacZ 
activity.  
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Figure 3.2 LacZ activity of EvgS mutants 
 
To check the effect of EvgS mutations on the activity of AR2 network, strains were assayed for lacZ activity.  
The already studied and showing lacZ activity mutant was taken as positive control and  pBAD 24 (Vector only) 
was taken as negative control. The level of lacZ activity is different for each mutant. All of the data points and 
error bars represent the average and standard deviation of 3 independent biological repeats respectively. 
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3.3 Acid resistance assay of EvgS mutants 
Characterization of the lab based evolved strains could increase our understanding of acid 
resistance in E. coli. Acid resistance is regulated by a complex network; mutations in this 
network could give rise to an acid resistant phenotype. Studying the accumulation and 
tolerance of such mutations in regulatory networks could provide insights into the robustness 
and evolvability of bacterial networks.  
 
As mentioned earlier, EvgS mutants would be expected to contribute into acid resistance 
phenotype. In order to robust the hypothesis, these mutants were taken forward for acid 
resistance assay as described in methods.  
 
% Survival at pH 2.5 with respect to pH 7.0 is shown (fig 3.3). The EvgS mutant which is 
already studied and showing acid resistance was taken as positive control, whilst pBAD24 
(Vector only) was taken as negative control. The Fig 3.3 B explains the pattern of % survival 
at pH 2.5 with respect to pH 7.0 for EvgS mutants. Each assay was done in triplicates and 
standard deviation was calculated. 
 
Since pH 7.0 shows highest survival in all bacterial strains, pH 7 was assigned 100% 
survival.  
The data about % survival at pH 2.5, implicated that previously known acid sensitive strains 
have turned into acid resistant on lab based experiments. Thus it is shown that, the EvgS 
mutations could be confirming acid resistance phenotype. 
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Finding and understanding the mutations that confer this increased resistance could enhance 
our understanding of acid resistance regulation in E. coli. 
 
 
 
 
 
Figure 3.3 % Survival at pH 2.5 
The figure describes % Survival at pH 2.5 with respect to pH 7 for EvgS mutants. The already studied and 
showing lacZ activity mutant was taken as positive control and  pBAD 24 (Vector only) was taken as negative 
control. survival rate is different for each mutant All of the data points and error bars represent the average and 
standard deviation of 3 independent biological repeats respectively. 
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3.4 Correlation between AR assay with LacZ activity 
In order to analyze the correlation between % Acid Resistance and LacZ activity of the EvgS 
mutants, the linier graph was plotted. To check this, only 4 independent mutants (i.e A, B, C 
and D) are taken for the consideration as, rests of the mutants are same as one of these 4 
mutants.  
 
 R
2 
Value from Figure3.4 suggests a very good correlation between lacZ activity values and 
% survival at pH 2.5 of the EvgS mutants. This strongly supports the hypothesis about the 
EvgS mutants that shows acid resistance phenotype. 
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Figure 3.4 Survival at pH 2.5 V/S Lac Z activity 
In order to analyze the correlation between % Acid Resistance and lacZ activity of the EvgS mutants, the linier 
graph was plotted. R
2 
Value suggests a very good correlation between lacZ activity and % survival at pH 2.5 of 
the EvgS mutants. All of the data points and error bars represent the average and standard deviation of 3 
independent biological repeats respectively. 
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3.5 Screening for Clone of A) pBAD EvgS his mutant B) pBAD EvgS his mutant 
ΔSwa/Psi 
Previous study in Lund laboratory showed that, the SwaI/PsiI deletion from the otherwise 
wildtype gene shows no lacZ activity at either pH 7.5 or pH 5.7. Therefore it requires 
combination with constitutively activating mutations in order to check whether the deletion 
disrupts the ability of protein to detect acid. In order to check this hypothesis, we have cloned 
pBAD EvgS his mutant and pBAD EvgS his mutant ΔSwaI/PsIi. Three Constitive mutants , 
A,B and C are used as insert in both the cases.  
 
In order to screen the clones, restriction digestion of ligated product of pBAD EvgS-his 
mutant, and EvgS-his mutant/ΔSwaI-PsiI with SalI was performed as described in materials 
and methods. The (fig. 3.5 A) explains the insert size for respective clones. Undigested 
plasmids were taken as control. Once the cloning for each constitutive mutants were 
confirmed, these strains then taken forward to calculate the lacZ activity in order to check 
role of SwaI/PsiI deletion in lacZ activity. 
 
The fig (3.5 B) suggests that that there is always a slight drop in lacZ activity with the 
∆SwaI/PsiI mutation as compared to full length pBAD EvgS his , however, activity is still 
clearly very much higher than in the negative control. As region SwaI/PsiI with different 
genetic background shows lacZ activity which suggests that deletion of region may have 
affected the activity of the protein to detect acid when it is combined with constitutively 
active mutants. 
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Figure 3.5 (A) Screening for Clone of A) pBAD EvgS his mutant B) pBAD EvgS his mutant ΔSwa/Psi 
In order to check role of SwaI/PsiI deletion on lacZ activity, pBAD EvgS his mutants and pBAD EvgS his 
mutants ΔSwaI/PsiI were cloned. Three constitive mutants, A, B and C are used as insert in both the cases.  
Lane 1: Undigested pBAD/EvgS-his, Lane 2-4: Restriction Digestion with SalI for pBAD EvgS his mutants, A, 
B and C respectively, Lane 5-7: Restriction Digestion with SalI for pBAD EvgS his mutants ΔSwaI-PsiI, A, B 
and C respectively, Lane 8: Undigested pBAD EvgSHis ∆Swa/Psi, Lane 9: Hyperladder I. 
   
 
 
Figure 3.5 (B) LacZ activity of  pBAD EvgS his mutant B) pBAD EvgS his mutant ΔSwa/Psi 
To check role of SwaI/PsiI deletion on lacZ activity the above mentioned strains were taken forward to evaluate 
the lacZ activity. The figure suggests that that there is always a slight drop in lacZ activity with the ∆SwaI/PsiI 
mutatant as compared to full length pBAD EvgS his , however, activity is still clearly very much higher than in 
the negative control. 
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In 2003, Eguchi group showed that, a constitutively active mutant of EvgS conferred multi-
drug resistance (MDR) to an acrA knockout Escherichia coli. This linked two-component 
system EvgAS with the expression of the MDR system. In order to check the hypothesis 
regarding link between EvgAS system with respect to MDR, we have constructed some 
strains with different genetic background. 
 
The MG1655/pBAD24/∆acrA strain was obtained from BW25113/∆acrA::kan by phase P1 
transduction as described  in methods.  In order to confirm the mutation transfer, colony PCR 
(Fig 3.6-A) was carried out with following combination of primers. Primers 1 and 2, Primers 
1 and 4, Primers 3 and 2. Refer schematic representation, Fig 3.6 B. 
 
The change in band size in lane 2, 3 and 4 in figure 3.6-A. is due to various products obtained 
from PCR with different set of primers, resulting in amplification of each respective region. 
Lane 7 and 8 does not show any band, as kanamycin markers were used in this particular 
PCR which could not amplify the specific region as the MG1655/pBAD24 strain does not 
have kanamycin cassette within.  
 
The gel picture suggests that the mutation along with kanamycin cassette is transduced into 
MG1655 strain in order to obtain MG1655/pBAD24/∆acrA:: kan. Once transfer of mutation 
was confirmed, kanamycin cassette was removed as described in methods, which was then 
confirmed by colony PCR with appropriate set of primers (Fig 3.6-C). MG1655/pBAD24 was 
taken as control. MG1655/pBAD24/∆acrA::kan was loaded as a negative control. The 
controls were used in order to confirm the result about removal of kanamycin cassette.  
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Once the strain, MG1655/pBAD24/∆acrA was obtained then these candidates were taken 
forward for efflux assays, as described in methods. This was done to understand the 
relationship between the two-component system EvgAS and the expression of the MDR 
system. 
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Figure 3.6 (A) Colony PCR: P1 Transduction. 
The MG1655/pBAD24/∆acrA strain was obtained by P1 transduction and confirmed by colony PCR using 
different sets of primers. Lane 1, 5: Hyperladder 1, Lane 2-4: MG1655/pBAD24/∆acrA using sets of primers 1+ 
2, 1+4 and 3+2 respectively. Lane 6-8: MG1655/pBAD24 PCR using Primer 1+ 2, 1+4 and 3+2 respectively. 
Refer Schematic representation of acrA::Kan (Fig 3.6-B) 
 
 
Figure 3.6 (B) Schematic representation of acrA::Kan 
Schematic representation of MG1655/pBAD24/∆acrA strain is shown. 
 
 
Figure 3.6 (C) Colony PCR: Removal of Kanamycin cassette 
Removal of kanamycin cassette was confirmed by colony PCR. 
Lane1: Hyperladder I, Lane2: MG1655/pBAD24/∆acrA:: kan, Lane3: WT MG1655 contro,.Lane4-9: 
Candidates showing loss of Kanamycin cassette. 
3.7 Efflux Assay 
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Membrane transporters or efflux pumps have been found in both prokaryotes and eukaryotes. 
Notably, some of these extrusion transport apparatus allow cells to achieve cellular self-
defense mechanisms and resistance to noxious compounds, leading to multi-drug resistance 
(MDR) (Xu et al., 2003).  H33342, used in our studies is a substrate for efflux pumps such as 
AcrAB-TolC. AcrA has a role as periplasmic adaptor protein (PAP) in most of the resistance 
nodulation division (RND) tripartite efflux pumps. AcrAB-TolC is considered one of the 
most important efflux pumps. This system discusses about innate multiple antibiotic 
resistance (Jessica etal., 2009).  
 
Previous study confirmed constitutively active mutant of EvgS (histidine kinase sensor) as 
multi-drug resistance (MDR) when it was deﬁcient in acrA in Escherichia coli. This linked 
two-component system EvgAS with expression of the MDR system (Eguchi  et al., 2003). 
 
The objective of this experiment is to compare the fluorescence intensity of 2.5 µM bis-
benzimide (Hoescht H33342) by various strains with reduced susceptibility to antibiotics. 
The strains with MG1655/∆arcA/pBAD24 background were processed for efflux assay along 
with respective MG1655/pBAD24 control strains. Graphs were plotted containing 
fluroscence against time for each strain having respective controls for each. Comparative 
analysis of bis-benzimide accumulation into the cell was done (fig 3.7 A-H). A Change in 
molecular flux of H33342 reflects permeability or efflux activity. Bis-benzimide was used as 
a fluorescent marker. These dyes accumulate within cells and intercalate with DNA and thus 
change fluorescence wavelength optima, (Excitation 350 nm, Emission 461 nm) therefore 
this fluorescence is considered as marker of intracellular accumulation of drugs. 
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Figure 3.7 A-H Efflux Assay using  bis-benzimide as a substrate. 
Comparative analysis of bis-benzimide accumulation into the cell was done. Accumulation of bis-benzimide by 
the strains with MG1655/∆arcA/pBAD24 background was processed for efflux assay along with respective 
MG1655/pBAD24 control strains. The figures (A-H) suggest that, in each case, ∆acrA mutants accumulate more 
bis-benzimide as compared to respective control strains. 
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As mentioned, the fluorescence activity is always linked to differences in pump activity 
between strains. The graphs plotted (Fig 3.7 A-H) suggest that accumulation of bis-benzimide 
by strains with MG1655/pBAD background is less than respective ∆acrA mutant. This is 
because these ∆acrA mutants lacking components of the major AcrAB-TolC efflux system. 
Thus they accumulate more bis-benzimide due to their lack of efflux activiy and allow cells 
to achieve cellular self-defense mechanisms and resistance to noxious compounds, leading to 
multi-drug resistance (MDR). This supports previous findings confirming the role of EvgAS 
system in expression of genes that confirms resistance to the drugs.  
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The research into the mechanism of response to acid stress in E. coli has revealed a very 
complicated regulatory network, to which, this study has supplementary contributions. Our 
studies regarding mutagenesis and phenotypic assays have been useful for better 
understanding of the acid resistance phenotype. 
 
The results presented in this report suggest that, the mutations characterized by genome 
sequencing included evgS mutations that were found in all evolved strains. EvgS is the HK of 
the EvgAS TCS that has been shown to respond to mild acid shock and activate acid 
resistance genes. The evgS mutations were found to be located in PAS domain of the EvgS 
protein. The evgS mutations were characterized and it is found that these mutations confirmed 
high level of acid resistance and AR2 promoter activity, which proposed that evgS mutations 
have altered the structure and consequently function of EvgS protein, therefore caused it to 
become constitutively on. The AR2 network, when it is normally inactive, seen to be 
activated by EvgS which was dissected by analyzing acid resistance in an EvgS strain in 
different knockout background. The results indicated that EvgS mutations confer an acid 
resistance phenotype and activation of AR2 network. The mutations characterized by this 
study could provide insights into the function of EvgS protein. 
 
Another part of our study was to understand the connection between the EvgAS system and 
multi-drug resistance (MDR) expression using efflux assay. Our results demonstrates that 
AcrA, the most important tripartite efflux pumps is a vital component of the efflux process 
and without that proficient efflux activity is significantly reduced. This supports previous 
hypothesis that the AcrA has an active role in the pump activity.  
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Additional exploration of this network will elucidate the physiological function of the EvgAS 
system and recognize the environmental signal to which EvgS responds. This particular study 
will provides platform in order to understand the mechanism of multi drug resistance in E. 
coli. 
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ABSTRACT 
Mycobacterium smegmatis is fast growing and nonpathogenic bacterium which has cell wall 
structure similar to the Mycobacterium tuberculosis, which is a causative agent of tuberculosis 
(TB) in humans. In order to identify and study the genes which are involved in the synthesis of 
mycobacterial cell wall components, M. smegmatis is extensively been used as a model 
organism mainly due to availability of their genome sequences. 
Most of the antitubercular drugs target the cell wall containing mycolyl-arabinogalactan-
peptidoglycan complex which is essential in mycobacterial sp such as M. tuberculosis. Mycolic 
acids are essential components of the mycobacterial cell wall. In this study, we confirmed that 
gene encoding permease can be deleted in M. smegmatis without affecting cell viability. 
Deletion/knockout of MSMEG4721, ortholog of M. tuberculosis Rv2508 significantly modified 
the culture characteristics when compared with wild type. Mutant with altered phenotype were 
further complemented with their respective orthologues in mycobacteria in order to 
characterize their functions. In this study we have identified and characterized this particular 
mutant which is found to be involved in the process of mycolic acid reduction. 
Altogether, the identification and characterization of such cell wall biosynthetic drug targets is 
promising research subject especially with the occurrence of multidrug-resistant tuberculosis 
(MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) strains. The findings in this 
study not only help to understand complexities of mycobacterial cell wall biosynthesis but also 
denote potential new drug target for tuberculosis. 
Keywords: Tuberculosis, Mycobacterium smegmatis, Mycolic acid biosynthesis, 
MSMEG4721, Rv2508. 
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1.1 Tuberculosis 
The mycobacteria causing tuberculosis (TB) is commonly found infectious disease in humans, 
which can cause severe illness or even death throughout the world. The World Health 
Organization (WHO) estimated that in spite of vaccination of Bacille -Calmette Guerin (BCG), 
nearly one-third of the world population is infected by Mycobacterium tuberculosis. The 
situation has even worsened because of the presence of some most considering factors like, 
limited response to chemotherapy, HIV co-infection, changing efficiency of BCG vaccine and 
most importantly occurrence of multidrugresistant TB (MDR-TB) (Culliton et al., 1992, Butler 
et al., 2000). Moreover, in 2011, at least once case of extremely-drug resistant TB (XDR-TB) 
had been reported by 55 countries worldwide (WHO 2011).  
 
The current increase in number of TB cases and especially occurrence of drug resistant 
mycobacteria indicate crucial requirement of novel anti-TB drugs. Existing anti- TB drugs 
cannot effectively kill the M. tuberculosis as the organism becomes persistent due to long 
duration of TB treatment. Recent developments in understanding the biological mechanism of 
the organism and the accessibility of the genome sequence give a chance to explore a wide 
spectrum of new targets for anti-TB drugs. It is proposed that the application of microarray and 
proteomics as genomic tools, if combined with recent approaches, such as structure-based drug 
design and discovery of new molecular scaffolds will surely lead to the development of new 
drugs that will certainly achieve effective control. 
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1.2 Mycobacterial cell wall 
The complex structure of mycobacterial cell wall plays a vital role in drug resistance and 
virulence (Karakousis et al, 2004). The compositional complexity of mycobacterial cell wall 
(Fig 1.1) distinguishes mycobacterium species from the majority of the other prokaryotes. It is 
classified as Gram positive bacterium, however, their envelope share notable features with gram 
negative cell wall such as outer permeability barrier acting as pseudo-outer membrane (Bernan 
et al., 1995).  
The structural features of the cell wall envelope can be divided into three major components, 
1. Plasma membrane. 
2. The mycolyl-arabinogalactan-peptidoglycan (mAGP) complex (Besera & Bernan, 1997), 
consisting of three covalently linked macromolecules, peptidoglycan (PG), 
arabinogalactan (AG) and hydrophobic mycolic acids which decorate the non-reducing 
terminus of arabinan domains. 
3. Lipoarabinimanan (LAM), lipomanan (LM), non-covalently bound lipids and 
glycolipids. 
Such a unique arrangement in the outer envelope lowers the permeability to hydrophobic small 
molecule and renders resistant to many drugs (Brennen and Nikaido, 1995). Besides their 
functional role, these glycoconjugates are also responsible for the modulation of host response 
during infection (Chatterjee & Khoo, 1998, Maeda et al., 2003). Most of the genetic elements 
involved in their biosynthesis are essential for the survival of Mycobacterium tuberculosis 
therefore they represent potential drug targets. 
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1.3 Mycobacterial cell wall: As a drug target 
In case of MDR and XDR strains of Mycobacterium tuberculosis, the antibacterial compounds 
which can act on actively growing bacterium may help toward the treatment of TB (Bhowruth et 
al., 2007). In this context, cell wall inhibitors are widely used targets of chemotherapy. Agents 
such as INH and EMB which are inhibitors of mycolic acids and arabinogalactan (AG) 
biosynthesis respectively have proved highly successful against combating the disease (Bhatt et 
al., 2007, Bhowruth et al., 2008). However due to development of drug resistant strains, 
certainly, the identification of novel drug targets and ultimately development of active 
compounds against them is an urgent requisite. In this respect the biosynthetic mechanism of 
mycobacteroial cell wall signifies an striking drug target (Bhatt et al., 2007). 
  
Fig 1.1 Diagramatic illustration of mycobacterial cell wall. Adapted from Minnikin et al (2002). 
The cell envelope consists of a cell wall core, plasma membrane, a capsule and an outer membrane. 
Lipoarabinimanan (LAM), mycolyl-arabinogalactan-peptidoglycan (mAGP), phthiocerol dimycocerosates 
(PDIM), peptidoglycan (PG), sulfated tetra-acyl trehalose (SL), diacyl trehalose (DAT), penta diacyl trehalose 
(PAT), trehalose monomycolate (TMM), trehalose dimycolate (TDM), N-acetyl muramic acid (NAM), N-acetyl 
glucosamine (NAG) and arabinogalactan (AG). 
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1.4 Mycolic acid synthesis 
Mycolic acids are integral part of mycobacterial cell wall, existing in either free form, bound to 
trehalose or associated with surface sugars making it complex mesh like structure. The 
significance of mycolic acids for mycobacteria has been discussed above. It is for this reason the 
biosynthesis of mycolates has been seen as a probable target for drug development.  
 
Mycolates are produced by two distinct systems, Type I and type II fatty acid synthases (FAS-I 
and FAS-II) in Mycobacterium sp (Fig 1.1).The biogenesis of mycolic acid takes place in 4 
stages (Brennan and Nikaido, 1995). 
 
1. Synthesis of C24-C26 straight chain saturated fatty acids to produce C-1 and C-2 atoms 
and the α-alkyl chain. 
2. Synthesis of  meromycolic acids (C40-C60 acids) to deliver a main carbon backbone. 
3. Modification of this backbone to produce other functional groups. 
4. Condensation reaction to produce premycolic acid which on reduction produces mature 
mycolic acid. 
 
The Mycolic acid synthesis is accomplished by concerted effort of FAS-I and FAS-II system. A 
particular gene fab (Rv2524c), encodes the multifunctional FAS-I system of M. tuberculosis. 
The gene expressing a protein forms homodimer, having domains of enoyl reductase, 
acyltransferase,, malonyl/palmitoyl transferase, dehydratase,,ϐ-keto acyl reductase, ϐ -ketoacyl 
synthase and acyl carrier protein, generating short chain fatty acyl-coA derivative for further 
elongation by FAS-II and to hexacosanoyl-S-coA for final condensation step (Takayama et 
al,2005).  
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FAS-II consists of group of enzymes elongating the fatty acyl-coA substrates into C-56 mero 
mycolate. In the first cycle, C16 acyl-AcpM is directly reduced by a ϐ-ketoacyl-AcpM reductase, 
FabG1 (MabA, Rv 1483) reduction via an enoyl-AcpM reductase. InhA (Rv 1484) (Gurvitz et al 
2008).After the first cycle, MtfabH is replaced by KasA/KasB (Rv 2245/46) (Marrakchi et al., 
2002) which is followed by dehydration catalyzed by a ϐ-hydroxyacyl-AcpM dehydratase (Rv 
0636) (Brown et al., 2007). KasA and KasB, the two discrete beta-ketoacyl synthases catalyze 
the condensation of the acyl-AcpM and malonyl-AcpM which results in a further increment of 
two carbon units (Fig 1.1) (Bhatt et al., 2005).After about 20 cycles FAS-II produces a 
meromycolic acid (C56) which then undergoes condensation reaction to form a pre-mycolic acid 
(Bhatt et al., 2007). 
 
The acetyl-CoA carboxylase,AccD4 and AccD 5,carboxylate C26-S_CoA after its synthesis by 
FAS-I and affords 2-carboxyl-C26-CoA.Simulteniously a fatty acyl-AMP ligase,Fad32(Rv3801c) 
converts meromycolic acid derived from FAS-II to meromycolyl-AMP(Trivedi et al., 2004). The 
2-carboxyl- C26-CoA and mature meromycolyl-AMP undergo the final Claisen type 
condensation is catalyzed by polyketide synthase-13,Pk13(Rv 3800) (Gande et al., 2004). 
Similar to FAS-I,Pks-13 also has multidomain structure with two phosphopantothein (PBP) 
domains, thioesterase (TE), acyl transferase (AT) and ketoaacyl synthase (KS), domain. The 
condenasation reaction results in the formation of 3-Oxo-C78- mycolate which then reduced by a 
reductase (Rv 2509) and generates mature C78- mycolic acid. (Bhatt et al., 2008). The further 
step is not yet known, however it is hypothesized that the mature mycolic acid then reacts with 
trehalose 6 phosphate to yield phosphorylated trehalose monomycolate (TMM-P) (Shimkata & 
Minatogawa,2000) which is transported outside the cell by an ABC transporter after its 
dephosphorylation by a phosphatase through a mycolic acid carrier (Takayama et al.,2005). 
Further, mycolic acid is transferred to the arabinogalactan-peptidoglycan complex as well as 
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TDM and TMM by the antigen 85 complex in order to produce the arabinogalactan-mycolate 
and trehalose dimycolate respectively (Fig 1.1) (Takayama et al., 2005). 
 
 
 
Fig.1.2 Pathway for Mycolic acid biosynthesis in M. tuberculosis (Adapted from Bhatt et al., 2007) 
Malonyl Co-A to malonyl-AcpM coversion is carried out by mFabD. Further, it is ligated by mtFabH to FAS-I 
derived C14-Co-A.The FAS-II system continues to process  C16 acyl-AcpM product producing meromycolates (C56 ), 
followed by  meromycolate precursors ligation to a FAS-I synthesized C26  fatty acid that constitutes the α branch of 
the final mycolic acid. Mycolic acids are then formed by the condensation of the α-branch and the meromycolate 
with the help of polyketide synthase Pks 13. 
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1.5 Background of the project 
As described earlier, mycolates are a key element of the complex mycobacterial cell wall and 
consequently, disruption of mycolates is deleterious to cell survival. Many genes that have role 
in mycolate biosynthesis are thus shown to be essential and for this reason the enzymes involved 
in mycolate biosynthesis are seen as potential drug candidates. 
 
In order to study cell wall biosynthetic pathways, M. smegmatis is been used as a substitute 
for M. tuberculosis as it is fast-growing, non-pathogenic, and most importantly this particular 
strain allows knockout of some genes which are essential in M. tuberculosis (Bhatt et al., 2008). 
Thus, M. smegmatis is considered to be important organism in order to study cell wall 
biosynthesis genes.  Moreover, despite of difference in mero-chain modifications between these 
two species, enzymes responsible for mycolate biosynthesis are identical (Bhatt et al., 2008). 
 
Many antituberculosis drugs, such as ethionamide, isoniazid, and thiolactomycin, target enzymes 
of mycolic acid biosynthetic pathway as this particular pathway is essential for mycobacterial 
survival. Previous reports from Dr. A. Bhatt’s labs suggests the role of  Rv2509 in mycobacterial 
mycolic acid biosynthesis by generating a deletion mutant of it’s homologue MSMEG4722 in M. 
smegmatis. They deleted the gene encoding a reductase which was shown to be  involved in the 
mycolic acid reduction in Mycobacterium smegmatis. Deletion of this particular gene did not 
affect the cell viability but altered culture characteristics and antibiotic sensitivity, emphasizing 
the potential of Rv2509 as a “secondary” drug target (Bhatt et al., 2008). This study probed the 
role of the extended region surrounding Rv2509. 
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Taking the above study as a platform, we hypothesized that MSMEG4721, which is the 
homologue of 2508c in M. tuberculosis and it is in the same cluster as of MSMEG4722 may 
have some significant role in mycolic acid biosynthesis. This hypothesis with respect to 
molecular mechanism of mycolic acid biosynthesis in mycobacteria has been tested by 
construction of a deletion knockout of MSMEG4721 followed by characterization of the mutant 
strain. 
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1.6 Aim and objectives 
Mycobacterial diseases are especially problematic to treat owing to the lipid-rich cell wall 
architecture. The mycobacterial cell wall is important for it’s growth and survival. Due to 
development of MDR and XDR-TB cases leading to discover of novel drug targets and specific 
antimycobacterial compounds against them. (Telenti et al., 1997).  
 
The literature review has described the mechanism of mycolic acid biosynthesis in 
mycobacteria. The aim of the project was to study molecular mechanism of lipid biosynthesis in 
mycobacteria by making deletion mutant of MSMEG4721 in M. smegmatis mc
2
 155 which is in 
the same gene cluster as  MSMEG4722, a gene encoding a reductase which had already shown to 
be involved in the final step of mycolic acid biosynthesis. 
 
To check this, following objectives were planned to understand the role of MSMEG4721. 
 To construct deletion mutant of MSMEG 4721. 
 Characterization of mutant: To understand the role of MSMEG 4721 in mycolic acid 
reduction. 
 Complementing the gene in order to restore WT M. smegmatis mc2 155 conditions. 
Characterization of the lab based genetically modified strain would certainly help to understand 
the importance of this particular gene involved in mycolic acid biosynthesis. 
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2.1 Plasmids, Bacterial Strains, and Phages Used in This Study 
 Description Reference 
Plasmids 
 pMV261 E. coli-Mycobacterium shuttle plasmid vector 
withhsp60 promoter and Kan
R
 cassette (aph) 
Stover et al. 
(1991) 
 pMV261-MSMEG471 MSMEG4721 cloned in pMV261 This work 
 pMV261-Rv2508 Rv2508 cloned in pMV261 This work 
 pΔMSMEG4721 Derivative of p0004s designed for allelic exchange 
ofM. smegmatis MSMEG4721 
This work 
Bacterial strains 
 mc
2
155 Electroporation-proficient ept mutant of M.  
megmatisstrain mc
2
6 
Snapper 
et al. (1990) 
 ΔMSMEG4721 Deletion mutant of mc2155 in which MSMEG4721 is 
replaced by hyg 
This work 
 ΔMSMEG4721-C Complemented strain of ΔMSMEG4721 containing 
pMV261-MSMEG4721 
This work 
 ΔMSMEG4721-CRv Complemented strain of ΔMSMEG4721 containing 
pMV261-Rv2508 
This work 
 Phages 
phΔMSMEG4721 Derivative of phAE159 obtained by cloning 
pΔMSMEG4721 into its unique PacI site 
Obtained 
from lab. 
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2.2 Chemical, reagents and growth condition 
All solvents and chemicals were ordered from Biorad (CA, USA), Fischer chemicals, UK and 
Sigma-Aldrich (Dorset, UK). Enzymes were purchased from Sigma-Aldrich (Dorset, UK), 
Roche (Lewes, UK) or New England Biolabs (Boston, USA) and were the highest grade 
available. All chemicals and solvents were AnalR grade. 
 
2.3 Bacterial growth condition 
E. coli was grown at 37°C, unless stated and with aeration at 180rpm in shaking incubator.  
Luria Bertani broth (LB : 0.5% w/v yeast extract, 1% w/v tryptone, 1% w/v salt; pH 7) was used 
for standard growing conditions. LB agar (LB broth + 1.5% w/v bacto agar; pH 7) was used 
where plating of bacteria was required. Both LB and LB agar were made up in distilled water 
and sterilized by autoclaving. 
M .smegmatis strains were grown in Tryptic soy broth (TSB, Difco), containing 0.05% Tween 
80 (TSBT). M .smegmatis and mycobacteriophase were also propagated on Middlebrook 7H9 
broth (Difco), with 0.2% glycerol and 0.05% Tween 80. Nutrient agar was made by adding 1.5% 
agar to above mentioned broth. The concentration of antibiotics for M .smegmatis were 25 µg/ml 
for kanamycin and 100 µg/ml for hygromycin-B. 
 
2.4 General Molecular Biology Techniques  
2.4.1 Plasmid Preparation E.coli strains.                    
This method is used to isolate the plasmid DNA from bacterial cell overnight culture containing 
appropriate antibiotic. The plasmid was isolated using Quagen plasmid mini kit as per 
manufacturer’s instruction. 
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2.4.2 Preparation of Competent cells for E.coli strains. 
 One ml of appropriate overnight culture was scaled up to 100 ml fresh LB media in a 250 ml 
conical flask. 20mM MgSO4 was added to it. This was grown at 37°C with shaking (180rpm) 
until the culture reached an OD (A600nm) of 0.4 to 0.5. It was followed by incubation on ice for 
30 minutes. The cultures were then pelleted (4000 rpm, 4°C, 10 minutes)  and the supernatant 
was removed by decanting then pellet was re-suspended in 40 ml of ice cold TFB1 (30 mM 
Potassium acetate,10 mM CaCl2, 50 mM MnCl2, 100 mM RbCl, 15% Glycerol, pH was adjusted 
to 5.8 with 1M acetic acid). The cells were incubated on ice for 5 minutes and then pelleted 
(4500 g, 4°C, 10 minutes). The supernatant removed by decanting and the pellet was re-
suspended in 4 ml of TFB2 (10 mM MOPS, 75 mM CaCl2, 10 mM RbCl, 15% Glycerol). It was 
then split into 200 µl aliquots for the use of transformation. 
 
2.4.3 Plasmid Transformation  
 An aliquot of competent cells was thawed on ice and Plasmid DNA (~50-70 ng) was added to it 
and the contents were mixed properly by swirling the eppendorf gently. The mixture was kept on 
ice for 10 minutes. Heat shock was given at 42
o
C for 45 seconds. 0.9 ml LB was added to it and 
incubated at 37°C for 1 hour in a shaker incubator. The transformed cells were then spin at 6000 
rpm for 5 minutes, supernatant was decanted, with the exception of 100µL and resuspended the 
pellet in this 100uL and plated onto selective agar. 
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2.4.4 Genomic DNA preparation of M. smegmatis. 
Once 10 ml M. smegmatis culture reached an OD (A600nm) of 0.8-1, it was pelleted down at 4500 
rpm for 15 minutes at room temperature. Supernatant was discarded. 500 µl of P1 buffer 
(Quagen mini kit) containing 50 mg/ml freshly added lysozyme. It was then mixed and 
incubated at 37 
o
C for 4 hours. 100 µl 10% SDS and mixed gently. Further, 50 µl 10 mg/ml 
Proteinase K was added freshly and incubated at RT for 1 hour. To that, 200 µl 5 M NaCl was 
added and mixed gently. Equal volume of chloroform was added and mixed by inverting which 
was followed by spin at 13,000 rpm for 10 minutes. Supernatant was transferred to new tube. 
Chloroform step was repeated again. Further, 0.7 volume of isopropanol was added and mixed 
by inverting. Tubes were incubated for 30 minutes at RT, followed by spin at 13,000 rpm for 15 
minutes. Pellet was then washed with ethanol. Further pellet was air dried and dissolved in 30 µl 
of elution buffer in order to obtain genomic DNA. 
 
2.4.5 Preparation of electrocompetent M. smegmatis cells 
1 ml of overnight culture was scaled up to 100 ml fresh TSB media in a 500 ml conical flask.  
This was grown at 37°C with shaking (180rpm) until the culture reached an OD (A600nm) of 
0.6. Further culture was shifted on ice .The culture was then pelleted (4000 rpm, 4°C, 30 
minutes). The supernatant removed by decanting and then the pellet was washed 3 times with 
10% Glycerol. (Filter sterilized). Finally the pellet was re-suspended in 1 ml of 10% glycerol. 
Aliquots were then used for electroporation  
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2.4.6 Electroporation 
10 μl of DNA was added to 100 μl of electrocompetent cell aliquots and mixed by flicking.  
Electroporation cuvettes were pre-chilled prior to use. The competent cell/DNA mix was 
pipetted into the electroporation cuvette. The samples were then electroporated using appropriate 
voltage as described earlier (snapper et al., 1990). 1 ml TSB was added to it and it was shifted to 
15 ml Falcon tube and incubated at 37°C for 1 hour in a shaker incubator. The transformed cells 
were then spun at 8000 rpm for 5 minutes. Supernatant was decanted, with the exception of 100 
µl and resuspended the pellet in this 100 µl and plated onto selective agar. 
 
2.4.7 Gene Cloning 
PCR amplification  
Gene of interest was used as a template for amplification. Specially designed primers were used 
for PCR amplification. Gradient PCR machine was used to amplify the gene and standardize the 
annealing temperature. Gradient was kept between 65°-75°C. The amplified products were 
checked on 1% agarose gel and the size confirmed by loading a 1kb DNA ladder. The 
temperature which was found appropriate was used to amplify the gene. 
 
Restriction digestion of vector and inserts  
Once the amplified genes were obtained, restriction digestion was carried out for the vector and 
gene insert. The specific restriction enzymes were used to cut both the vector and the genes at 
specific sites and generate overhangs so that both the vector and the insert can be ligated under 
appropriate conditions.  
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Ligation  
The digested vector with gene insert (In molar ratio 1:3) were then ligated with the help of T4 
DNA ligase in a reaction mix containing ligation buffer in final concentration of 1X. The 
ligation was carried out at RT for 10 minutes. Ligated product along with control (vector alone) 
was then transformed and plated on selective agar and kept at 37 
o
C overnight as described 
earlier. 
Clone screening 
The colonies obtained during ligation were then inoculated in liquid media along with 
appropriate antibiotic in order to obtain plasmid as described earlier. Plasmid was then digested 
with appropriate restriction enzymes and product was then run on 1% agarose gel along with 
control. Probable positive clones were then confirmed by sequencing. 
 
2.5 Construction of MSMEG∆4721 
The phasmid DNA of the knockout phage ph∆MSMEG4721 was already constructed at the start 
of this project. The recovered phasmid was further transformed into M. smegmatis strain via 
electroporation and then cells were grown at 30
o
C for 3 days to yield phase particles. Generation 
of high titre phase particles involved 200 µl of 0.8 OD600 nm.  Culture of M. smegmatis mixed into 
5 ml molten7H9 soft agar and overlaid on basal layer of 7H9 agar. The phase stock was serially 
diluted (10
-1
-10
-10
) with MP buffer (50mM Tris.HCl pH 7.8, 150mM MgSO4, 2mM CaCl2). Each 
dilution was spotted onto solidified overlay of M .smegmatis. Plates were incubated at 30
o
C for 3 
days, after which plaque forming units were counted and phase titre was calculated (pfu=number 
of pfu in spot*dilution factor*100). Original phase stock was diluted to yield approximately 500 
plaques per plate and mixed with 200 µl of M. smegmatis in molten 7H9 agar, which was 
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overlaid on solid 7H9 agar. . Plates were incubated at 30
oC for 3 days, resulting in “lacy 
pattern”. The high titre phase was then collected and filtered through 0.45 µM filter. 
In order to perform specialized transduction, M .smegmatis cultures were grown to 0.8 OD600 nm 
in 50 ml of TSB with 0.05%, Tween 80. Harvested cells were then washed three times with 50 
ml MP buffer and finally resuspended in 5 ml MP buffer.0.5 ml of cells was then mixed with 0.5 
ml of optimum high titre lysate (10
10
 pfu/ml) and incubated overnight at 37
o
C,followed by 
plating onto TSB agar plate with hygromycin B (100µg/ml ) . Plates were incubated at 37
o
C for 
1-2 weeks in order to obtain single isolated colonies. Deletion of MSMEG4721 was confirmed 
by southern blot. 
 
2.6 Southern blot analysis 
Southern blot analysis was used to confirm gene knock-out mutants and was performed as 
specified in Roche Applied Science kit protocol. PCR products of 1kb representing the left and 
right flanking regions of MSMEG4721 were used as probes. SacI digested genomic DNA form 
M .smegmatis WT mc
2
155 and M .smegmatis ∆4721 strains were subjected to the gel 
electrophoresis to separate the fragment. Following gel electrophoresis, the gel was depurinated 
(0.25 M HCl, 15 min) until the purple dye on gel turned yellow. The gel was then washed and 
put into denaturation solution for 15 minutes (1.5 M NaCl, 0.5 M NaOH) till the dye turned dark 
blue. The gel was washed and returned to neutralization solution (0.5 M Tris-HCl, pH 7.2, 1 M 
NaCl). The gel was subsequently transferred to positively charged nitrocellulose membrane via 
capillary action with 20xSSC (3 M NaCl, 0.3M sodium citrate, pH 7.0). DNA on membrane was 
covalently bound by crosslinking. The membrane was finally rinsed with distilled water and air 
dried. Probe preparation involved boiling at 105
o
C, snap freezing and labeling with digoxigenin-
dUTP, using DIG High prime DNA labeling and detection kit (Roche), as described in 
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manufacturer’s protocol. The membrane was exposed to the probe at 65 oC overnight, followed 
by washing and finally immunodetected with antibody for 30 min at 37
o
C. The hybridized 
probes were visualized with chemiluminescence. 
 
2.7 Construction of complemented strains 
MSMEG4721 gene was PCR ampliﬁed from parental M. smegmatis mc2155 genomic DNA 
using the specific primers followed by cloning into the E. coli-Mycobacterium shuttle plasmid 
pMV261 with the primer incorporated HindIII and EcoRI sites, to obtain recombinant plasmid, 
pMV261-MSMEG4721. Similarly, the plasmid pMV261-Rv2508 was also constructed with 
Rv2508, which was PCR ampliﬁed from M. tuberculosis H37Rv genomic DNA with specific 
primers. The complemented strains ∆MSMEG4721-C and ∆MSMEG4721-CRv were obtained by 
selecting on kanamycin. Colonies were screened by restriction digestion. Positive clones then 
were transformed by electroporation with pMV261-MSMEG4722 and pMV261-Rv2508. The 
complemented strains then were further used for lipid extraction along with ∆MSMEG4721 and 
WT mc
2
155 strains. 
 
2.8 Apolar lipid extraction from mycobacterial cell wall 
The strains ∆MSMEG4721, ∆MSMEG4721-C and ∆MSMEG4721-CRv along with WT mc2155 
were grown in 5 ml TSB at 37
o
C for 2 days. The cultures were labeled with [
14
C]-acetate (1µl/ml 
of culture). Next day, cells were pelleted down and used for lipid extraction. To the pellet 2ml of 
Methanol: 0.3% NaCl (10:1 v/v) and 1 ml of petroleum ether (60-80) was added. It was mixed 
on a rotator for 30 min, centrifuged at 4000 rpm for 5 min. The upper layer was transferred in a 
pre-weighed separate tube ‘B’. 2ml of petroleum ether was added into lower layer (tuber ‘A’), 
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mixed for 30 min on a rotator and then centrifuged for 5 min at 4000 rpm. Upper layer was 
transferred to tube ‘B’. Tubes were dried on heating block (50oC) under nitrogen in order to get 
apolar lipids. The dried pellet (Aploar Lipids) was resuspended in Chloroform: Methanol (2:1 
v/v) solution. 5 µl was used to take radioactive counts. 
2.9 Polar lipid extraction from mycobacterial cell wall 
Further, into Tube ‘A’, 2.3ml of Chloroform: Methanol: 0.3% NaCl (9:10:3) was added to the 
pellet. Mixed for 60 min on the rotator and spun it for 3 min at 3500 rpm. Supernatant was 
transferred into tube ‘C’.750 µl of Chloroform: Methanol: 0.3% NaCl (5:10:4) was added to the 
pellet of tube ‘A’. Mixed for 30 min on a rotator, spun at 3500 rpm for 3 min. Supernatant was 
pooled in tube ‘C’. This step was repeated once more to get Non-extractable Lipids (Tube ‘A’). 
To the pooled extract, 1.3ml of Chloroform + 1.3ml of 0.3% NaCl was added, mixed for 5 min 
on a rotator and centrifuged for 3 min at 3500 rpm. The lower layer was collected and 
transferred to tube ‘D’ using long glass Pasteur pipette. The extract in tube ‘D’ was dried on 
heating block (50
o
C) under nitrogen in order to get dry polar lipids. The dried pellet (Polar 
Lipids) was resuspended in Chloroform: Methanol (2:1 v/v) solution to get Polar lipids. 
 
2.10 TLC of apolar lipids 
Equal count of the resulting solution of apolar lipid was subjected to TLC .Plates used for this 
experiment were silica gel plates (5735 silica gel 60F254; Merck, Darmstadt, Germany). The 
samples were subjected to 2D-TLC System B .Direction 1 was Petroleum ether: Acetone (98:2 
v/v).Direction 2 was Toluene: Acetone (98:2 v/v). The analysis of apolar lipids was additionally 
done with 2D-TLC System c .Direction 1 was Chloroform: Methanol (96:4 v/v). Direction 2 was 
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Toluene: Acetone (80:20 v/v). Autoradiograms were obtained by overnight exposure of Kodak 
X-Omat AR film to the plates to reveal [
14
C]-labeled FAMEs and MAMEs. Data was analysed. 
 
2.11 Fatty acid methyl esters (FAMEs) and mycolic acid methyl esters (MAMEs) 
extraction and visualization by TLC 
For extraction of MAMEs, both the whole-cell pellets and delipidated cells were subjected to 
alkaline hydrolysis.this was done by 5% aqueous 2 ml of TBAH treatment at 95°C overnigh. 
Further, 4 ml CH2Cl2, 500 μl CH3I, 2 ml water was added in to it which was then followed by 
mixing for 30 min. The aqueous phase (upper layer) was discarded following centrifugation, and 
the organic phase (lower layer) was washed thrice with water and evaporated under N2 to dry. 
The resulting FAMEs and MAMEs were dissolved in 4 ml of diethyl ether, followed by 
sonication for 20 minutes. The residue (insoluble portion) was removed by centrifugation, and 
the ether solution evaporated to dryness and dissolved in 200 μl of CHCl3:CH3OH (2:1). 5 µl 
was used to take radioactive counts. Equal count of the resulting solution of FAMEs and 
MAMEs was subjected to TLC with silica gel plates and developed in petroleum ether-acetone 
(95:5). Autoradiograms having [
14
C]-labeled FAMEs and MAMEs were obtained by 
exposingplates to to Kodak X-Omat AR film for 10-12 hours. Data was then analyzed. 
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The literature review has described the mechanism of mycolic acid biosynthesis in 
mycobacteria. As described in methods, we made deletion  mutant of MSMEG4721 in M. 
smegmatis mc
2
 155 which is in the same gene cluster as  MSMEG4722, a gene encoding a 
reductase shown to be involved in the final step of mycolic acid reduction. The results will 
describe the functional link between these two genes. 
 
3.1 Construction and growth of mutant ∆MSMEG 4721 
To understand the role of MSMEG4721 (Homologue of Rv2508) in mycolic biosynthesis, we 
deleted MSMEG4721 in M. smegmatis mc
2
155 by specialized transduction (Bardarov et al., 
2002) (Figure 3.1-A). The ability to generate a knockout of this particular gene indicated 
that MSMEG4721 was nonessential for the viability of M. smegmatis mc
2
155. Deletion of 
MSMEG4721 was confirmed by southern blot as described in methods. There were two SacI 
restriction sites in the wild type and three in the mutant due to presence of hyg
R 
gene marker 
(Figure 3.1 A). Following SacI digestion, one fragment was observed for wild-type and two 
fragments for M. smegmatis∆4721 (Figure 3.1-B). 
Deletion of MSMEG4721 had significant change on the colony morphology in comparison 
with M. smegmatis mc
2
155 when grown on tryptic soy broth (TSB) agar. Precisely, the colonies 
of the parental, wild-type strain mc
2155 were glossy, and the mutant strain ΔMSMEG4721 had 
dry surface than that of wilt type strain (Figure 3.3). To check the hypothesis, whether an 
observed phenotype in the mutant strain is exclusively due to loss of MSMEG4721, we have 
cloned ∆MSMEG4721-C and ∆MSMEG4721-CRv and colonies were screened as described in 
methods. The figure 3.2 explains the insert size for respective clones. The respective phenotype 
on complementation of ∆MMSMEG4721 could restore wild type characteristics demonstrating 
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that the experiential phenotypes in the mutant strain were only due to the loss of MSMEG4721 
(Figure 3.3 B).  
 
 
Figure 3.1 Construction of  MSMEG4721 knockout 
A) Gene map of  MSMEG4721 region in the parental M. smegmatis strain mc2155 and its resultant region in 
the ΔMSMEG4721 mutant. hyg, hygromycin resistance gene from Streptomyces hygroscopicus; sacB, 
sucrose counterselectable gene from Bacillus subtilis. res, γδ resolvase site.  Digoxigenin-labeled are 
indicated by thick lines with diamond-shaped ends.  
B) SacI digested genomic DNA bands of strains of parental mc2155 and MSMEG∆4721 reflected on Southern 
blot are indicated in roman numerals. 
A                                                   
re
s
s 
res
s 
B                                                
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Figure 3.2 Clone screening  
Clone screening of MSMEG4721-C and Rv 2508-C by restriction digestion using HindIII and EcoRI restriction 
enzymes. Expected band sizes were 1293bp and 1338 bp respectively. 
 
 
 
Figure 3.3 Colony morphology of wild-type (mc
2
155), mutant (ΔMSMEG4721), and complemented 
(ΔMSMEG4721-C) strains. 
Colonies of wild-type (mc
2
155), mutant (ΔMSMEG4721), and complemented (ΔMSMEG4721-C) strains on TSB-
agar without Tween-80.Colony growth was obtained by inoculating 5 μl of a broth culture of each strain on agar 
plate.  
 
 
 
26 
 
3.2 Characterization of mutant ΔMSMEG4721 
As mentioned earlier, MSMEG4722, a gene encoding a reductase shown to be involved in the 
final step of mycolic acid reduction. (Bhatt et al., 2008). In order to identify the functional link 
between MSMEG4721 and MSMEG4722, characterization of mutant ΔMSMEG4721 was carried 
out. 
 
The detected changes in the colony morphology of the ΔMSMEG4721 mutant driven us to study 
mycolic acids in the respective mutant strain. The set protocol was used to release mycolic acids 
from mycobacteria. The procedure involves base hydrolysis of cells with the help of tetrabutyl 
ammonium hydroxide (TBAH). After this, phase-transfer catalyzed derivatization was done 
using methyl iodide resulting in the formation of mycolic acid methyl esters (MAMEs) (Dobson 
et al., 1985). This was then analyzed by thin-layer chromatography (TLC). The [
14
C]-labeled 
extracts obtained from base treatment and derivatization were analyzed by TLC. In the parental 
mc
2155 strain, presence of α, α′ and epoxy MAMEs were observed however all the three species 
were drastically reduced in the extract from the ΔMSMEG4721 strain (Figure 3.4-A). Instead, 
there was accumulation of a product(s) found to be migrated above the fatty acid methyl esters 
(FAMEs) bands in the mutant strain. The similar outcome was found for extracts from 
delipidated cells that comprises of only cell wall bound mycolates (Figure 3.4-B), which 
indicates that both total and specifically cell wall-bound mycolates shows modifications in 
mycolate profiles in parental and mutant strain. Figure 3.4 also suggests that mycolic acid 
biosynthesis was restored in the mutant strain when it was complemented with MSMEG4721 
and  Rv2508. This indicates that Rv2508 is a functional homolog of MSMEG4721 in M. 
tuberculosis (strains ΔMSMEG4721-C and ΔMSMEG4721-CRv, respectively (Figure 3.4-A).  
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As mentioned earlier, the significant reduction of α, α′ and epoxy MAMEs and the appearance of 
rapidly migrating species in extracts of the ΔMSMEG47221 mutant suggest that these rapidly 
migrating species are the precursors of mycolates. The above experimental results thus suggests 
that the ΔMSMEG4721 mutant accumulate precursors of mycolic acids in the cell wall (Bhatt 
etal., 2008). Thus MSMEG4721 and Rv2508 are shown to be involved in mycolic acid reduction. 
 
 
 
 
 
 
Figure 3.4 Visualization of Fatty acid methyl esters (FAMEs) and Mycolic Acid Methyl Esters (MAMEs) by 
TLC method. 
TLC examination of FAMEs and MAMEs extracted from ΔMSMEG4721, mc2155, ΔMSMEG4721-C, and 
ΔMSMEG4721-CRv strains. The speedily migrating species observed in ΔMSMEG4721 are labeled as precursors of 
mycolates in total (Fig 3.4-A) and specifically cell wall-bound mycolates (Fig 3.4-B). 
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3.3 Lipid Analysis of ΔMSMEG47221 mutant 
[
14
C]-acetate labeled apolar lipids were extracted from parental mc
2155, ΔMSMEG4721, and 
ΔMSMEG4721-C strains as described in methods. This was then studied by 2D-TLC. Moreover, 
the mutant strain was found to be accumulating nonpolar species as a result of complete loss of 
free mycolic acids. The respective lipid profile on complementation of ∆MMSMEG4721 could 
restore wild type characteristics indicating that the observed profile in the mutant strain were 
exclusively due to the loss of MSMEG4721 (Figures 3.5-B and 3.5-C).  
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Figure 3.5 Lpids extracted from parental mc
2
155 , ΔMSMEG4721and ΔMSMEG472-C strains in system B and  C                                                                                                                              
System B: Direction 1: Petroleum ether: Acetone (98:2) v/v. Direction 2: Toluene: Acetone (98:2) v/v. Ketones are 
indicated by an arrow. System C: Direction 1: Chloroform: Methanol (96:4) v/v. Direction 2: Toluene: Acetone (80:20) 
v/v.MA : mycolic acids. 
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This particular experimental data support the above mentioned evidence that the ΔMSMEG4721 
mutant accumulate precursors of mycolic acids in the cell wall, thus it has role in mycolic acid 
reduction in M. Smegmatis. 
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CHAPTER 4 
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The lipid-rich cell wall of mycobacteria play important role in physical protection and it is also 
responsible for virulence. Several currently used anti-TB drugs including ethionamide and 
isoniazid target cell wall biosynthetic pathways (Banerjee et al., 1994 and Kremer et al., 2000). 
Thus better understanding of the cell wall assembly and it’s biosynthesis will provide important 
clues for the development of novel anti-mycobacterial drug targets. 
 
The central objective of the studies described in this thesis was to study cell wall biosynthesis in 
mycobacteria which mainly focus on the post-fatty acid synthase-II/Pks13 processing. To 
achieve this, we generated a viable null mutant of MSMEG4721 which indicates that, it is 
nonessential gene. However our study has demonstrates that loss of function causes remarkable 
changes in the cell wall of M. smegmatis. Further characterization of this mutant suggests that 
the gene encoding permease is involved in mycolic acid reduction in Mycobacterium smegmatis. 
Moreover, characterization of Rv2508, the Mycobacterium tuberculosis homolog of 
MSMEG4721, suggests the potential of Rv2508 as a secondary drug target in M. tuberculosis.by 
showing it’s role in mycolic acid reduction.  
 
Combined outcomes based on previous studies in this lab and our current study suggests that the 
gene encoding reductase MSMEG4722 and gene encoding permease MSMEG4721, both are 
involved in mycolic acid reduction. In future, a very well established method, ‘mycobacterial 
protein fragment complementation’ based on yeast-two hybrid system can be used in order to 
understand the link between these two genes. 
 
32 
 
To conclude, the identification and characterization of such ‘cell wall biosynthetic drug targets’ 
is an important step in order to treat tuberculosis especially when there is occurrence of MDR-
TB and XDR-TB. Thus these studies put significant contribution in order to understand the 
complexities of mycobacterial cell wall biosynthesis and represent potential novel drug target 
against Tuberculosis. 
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